Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG +7.48%40 EV-to-EBIT is 12.60 as of Sep. 09, 2026, which is 9% above its 10-year median of 11.57. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 40/100. The stock has 5 warning signs investors should review. Among 682 Drug Manufacturers companies, Zenith Drugs ranks better than 59.53% on this metric.
The historical rank and industry rank for Zenith Drugs's EV-to-EBIT or its related term are showing as below:
NSE:ZENITHDRUG'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.12 Med: 11.57 Max: 23.02
Current: 12.6
During the past 6 years, the highest EV-to-EBIT of Zenith Drugs was 23.02. The lowest was 7.12. And the median was 11.57.
NSE:ZENITHDRUG's EV-to-EBIT is ranked better than 59.53% of 682
companies
in the Drug Manufacturers industry
Industry Median: 16.105
vs NSE:ZENITHDRUG: 12.60
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zenith Drugs's Enterprise Value for the quarter that ended in Mar. 2026 was ₹1,150 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹110 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs EV-to-EBIT Related Terms
Zenith Drugs EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's EV-to-EBIT falls into.
Zenith Drugs's current Enterprise Value is ₹1,386 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹110 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs (NSE:ZENITHDRUG) has a EV-to-EBIT of 12.60 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zenith Drugs and its competitors. This is near median its historical median of 11.57. Over the past decade, Zenith Drugs' EV-to-EBIT has ranged from 7.12 to 23.02. According to the industry distribution chart, Zenith Drugs ranks #276 out of 682 companies in the Drug Manufacturers industry, placing it in the top 40.5%.
Is Zenith Drugs' EV-to-EBIT too high?
Zenith Drugs' current EV-to-EBIT of 12.60 is near median its 10-year median of 11.57. Over the past 10 years, this metric has ranged from a low of 7.12 to a high of 23.02. The Drug Manufacturers industry median EV-to-EBIT is 16.11. Zenith Drugs' value of 12.60 is 21.8% below this industry median. Based on the distribution chart, Zenith Drugs ranks #276 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zenith Drugs has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #276 out of 682 companies for EV-to-EBIT. This puts Zenith Drugs in the upper half of its industry. The industry median EV-to-EBIT is 16.11. Zenith Drugs' value of 12.60 is 21.8% below this benchmark. Historically, Zenith Drugs' own EV-to-EBIT has ranged from 7.12 to 23.02 over the past decade. While the company's 10-year median is 11.57 vs. the industry median of 16.11, Zenith Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.11, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current EV-to-EBIT of 12.60 is 21.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current EV-to-EBIT is 12.60, which is near median its own 10-year median of 11.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current EV-to-EBIT of 12.60. The current EV-to-EBIT is 12.60, which is near median its 10-year median of 11.57 and 21.8% below the Drug Manufacturers industry median of 16.11. Zenith Drugs' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current EV-to-EBIT is 12.60 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
40GF Score
Get the complete analysis for NSE:ZENITHDRUG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
